Aβ monomers
modified Aβ forms
different forms of Aβ
CSF Aβ abnormalities
cerebral Aβ pathology
AD pathogenesis
disease progression
underlying molecular pathogenesis of AD
prognostic tools
CSF tau changes
new diagnostic
years
neuronal toxicity
pathologies
proposal
simple linear model of AD aetiology
prognostic biomarker tools
understanding of Alzheimer’s disease
Alzheimer's disease Critical
tau hyperphosphorylation
brain incubation
onset of symptoms
therapeutic research
broad view of AD’s multiple pathophysiological features
Aβ42 correlates
unique clinical materials
combination of groundbreaking technologies
cerebrospinal fluid
moities
humans
chemical modifications
defective clearance
putative biomarkers
key pathological factors
brains of certain individuals
therapies
amyloid beta
immune system
major questions
α-synuclein
Pathways
development of effective treatments
TDP
neurotoxicity
peptide
phenotypes
hypothesis
process
PATHAD